Schisandrin B

Drug Profile

Schisandrin B

Alternative Names: (-) schisandrin B; Sch B

Latest Information Update: 16 Oct 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hong Kong University of Science and Technology; MitoPharm Corporation
  • Developer MitoPharm Corporation
  • Class
  • Mechanism of Action Antioxidants; Mitochondrial protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Reperfusion injury

Most Recent Events

  • 16 Oct 2012 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
  • 16 Oct 2012 Discontinued - Preclinical for Reperfusion injury in USA (unspecified route)
  • 22 Jun 2007 Preclinical trials in Reperfusion injury in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top